

Shaping the future of healthcare

**WITH A ROBUST
PRODUCT PIPELINE**

FULL-YEAR 2018 SALES WORLDWIDE

\$30.6
billion

+7.3%¹
on organic basis*

**STRONG PERFORMANCE
IN CORE BUSINESS SEGMENTS²**

sales on organic basis*

+6.7%
DIAGNOSTICS

+9.1%
MEDICAL DEVICES

+5.2%
NUTRITION

+7.0%
ESTABLISHED
PHARMACEUTICALS

FULL-YEAR 2019 GUIDANCE³

\$3.15 to \$3.25
ADJUSTED EPS

MIDPOINT REFLECTS DOUBLE-DIGIT GROWTH

**30+ KEY PRODUCT
ADVANCEMENTS IN 2018**

INCLUDING:

**Amplatzer Piccolo™
Occluder, U.S.**

**Pedialyte® Sparkling
Rush™, U.S.**

**HeartMate 3™, Long-
Term Indication, U.S.**

**DRG Invisible Trial
System, U.S.**

FreeStyle Libre® 2, Europe

FreeStyle Libre® 14 Day, U.S.

**High Sensitive
Troponin-I, Expanded
Indication, Europe**

MitraClip®, COAPT Trial, U.S.

MitraClip®, U.S. and Japan

Ensure® Max Protein, U.S.

Advisor™ HD, U.S.

**Xience Sierra®, U.S.
and Japan**

Masters HP™, U.S.

**DELIVERING IMPRESSIVE
GROWTH THROUGH A STRONG
PRODUCT PIPELINE**

◀ **FreeStyle Libre® system:** Our revolutionary sensor-based continuous glucose monitoring system is one of the world's fastest-growing medical devices – with more than 1 million users.

Alinity™: Our new suite of diagnostic systems offers leapfrog-level innovation to provide ease of use, greater flexibility and a smaller laboratory footprint.

Structural Heart portfolio: Our minimally invasive solutions span the spectrum of heart valve disease and congenital heart defects.

CREATING SHAREHOLDER VALUE

14.3%

dividend increase
for 2019 payouts

\$2B

returned to shareholders
in the form of dividends
in 2018

REPAID MORE THAN

\$8B

of debt, enhancing our
strategic flexibility

*Organic sales growth excludes prior year results for the Abbott Medical Optics (AMO) and St. Jude Medical vascular closure businesses, which were divested during the first quarter of 2017; excludes the current and prior year results for Rapid Diagnostics, which reflect results for Alere Inc., which was acquired on October 3, 2017; excludes the prior year fourth-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third quarter of 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated January 23, 2019.

¹On a GAAP basis, Abbott sales increased 11.6%.

²On a GAAP basis, Diagnostics sales increased 33.5%; Medical Devices sales increased 10.1%; Nutrition sales increased 4.4%; and Established Pharmaceuticals sales increased 3.2%.

³Adjusted EPS excludes specified items. Full-year 2019 GAAP guidance of \$1.80 to \$1.90.

FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.